Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania. Show more

Location: 101 Lindenwood Drive, Malvern, PA, 19355, United States | Website: https://www.annovisbio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

44.43M

52 Wk Range

$1.11 - $10.54

Previous Close

$2.28

Open

$2.26

Volume

97,052

Day Range

$2.21 - $2.30

Enterprise Value

27.3M

Cash

17.13M

Avg Qtr Burn

-6.173M

Insider Ownership

14.78%

Institutional Own.

14.59%

Qtr Updated

06/30/25